GPC3 and neoplasm: To explore the targeted delivery ability of hGC33 scFv‐melittin MVs to GPC3‐positive tumor cells in vivo, we monitored the biodistribution of nP18 at 12, 24, and 36 h postintravenous injection by fluorescence imaging.